However, we think that this is unlikely as CRC cell lines with KRAS or BRAF mutations seem to preferentially activate the ERK1/2 pathway and when treated with ERK5 inhibitors, cell proliferation is unaffected [23,24]. This evidence concerns the gene BRAF and colorectal carcinoma.